Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0A8QA
|
||||
Former ID |
DNC014352
|
||||
Drug Name |
2-Chloro-5-(2-methylquinolin-7-yl)nicotinonitrile
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C16H10ClN3
|
||||
Canonical SMILES |
CC1=NC2=C(C=C1)C=CC(=C2)C3=CN=C(C(=C3)C#N)Cl
|
||||
InChI |
1S/C16H10ClN3/c1-10-2-3-11-4-5-12(7-15(11)20-10)14-6-13(8-18)16(17)19-9-14/h2-7,9H,1H3
|
||||
InChIKey |
FCXAJLFDBPZDJD-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Metabotropic glutamate receptor 5 | Target Info | Inhibitor | [1] | |
KEGG Pathway | Calcium signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
Gap junction | |||||
Long-term potentiation | |||||
Retrograde endocannabinoid signaling | |||||
Glutamatergic synapse | |||||
Huntington's disease | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Metabotropic glutamate receptor group III pathway | |||||
Metabotropic glutamate receptor group I pathway | |||||
Endogenous cannabinoid signaling | |||||
Reactome | G alpha (q) signalling events | ||||
Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
WikiPathways | Hypothetical Network for Drug Addiction | ||||
GPCRs, Class C Metabotropic glutamate, pheromone | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Bioorg Med Chem. 2010 May 1;18(9):3026-35. Epub 2010 Mar 27.Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic glutamate receptor subtype 5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.